ALKS On Other Exchanges

alkermes plc (ALKS) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALKERMES PLC (ALKS)

alkermes plc (ALKS) Related Businessweek News

View More BusinessWeek News

alkermes plc (ALKS) Details

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company’s marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

2,300 Employees
Last Reported Date: 02/15/19
Founded in 1987

alkermes plc (ALKS) Top Compensated Officers

Chairman & CEO
Total Annual Compensation: $2.2M
Co-Founder & Director
Total Annual Compensation: $89.0K
Senior VP & CFO
Total Annual Compensation: $859.5K
Senior VP of Medicines Development & Medical ...
Total Annual Compensation: $1.0M
Senior VP, Chief Legal Officer, Chief Complia...
Total Annual Compensation: $838.8K
Compensation as of Fiscal Year 2018.
alkermes plc
Alkermes plc Reaffirms Financial Guidance for 2019

Alkermes plc reaffirmed financial guidance for 2019, as it continue to position VIVITROL and ARISTADA for long-term growth, invest in the development pipeline and prepare for the potential launch of ALKS 3831. For the year ending Dec. 31, 2019, the company expects, revenue of $1,140 million to $1,190 million, net loss of $135 million to $165 million and net loss per share of $0.87 to $1.06.

Alkermes plc Reports Earnings Results for the First Quarter Ended March 31, 2019

Alkermes plc announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced total revenue was USD 223.102 million compared to USD 225.150 million a year ago. Operating loss was USD 76.001 million compared to USD 61.888 million a year ago. Net loss was USD 96.398 million compared to USD 62.505 million a year ago. Basic loss per share was USD 0.62 compared to USD 0.4 a year ago.

Alkermes plc Appoints C. Todd Nichols as Senior Vice President of Sales and Marketing, Effective May 13, 2019

Alkermes plc announced that C. Todd Nichols, an executive with more than two decades of extensive commercial experience in the biopharmaceutical sector, will become the company's Senior Vice President of Sales and Marketing, effective May 13, 2019. He will serve on the Alkermes executive management team and report to Richard Pops, the company's Chief Executive Officer. Todd joins the company from Celgene where he was responsible for developing and managing all aspects of U.S. commercial planning, strategy development and launch execution for ozanimod for multiple sclerosis.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALKS.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ALKERMES PLC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at